Not all heroes wear capes; some have pretty paws, like Oprah Winfrey‘s dogs! The iconic host gave an insider look The Oprah ...

New research found that antibiotics, antivirals, vaccinations and anti-inflammatory medicines are all associated with reduced ...

The obesity and diabetes markets are on the cusp of transformation, driven by cutting-edge GLP-1 therapies. Eli Lilly and Novo Nordisk are shaping the competitive landscape, with novel drugs like ...

The first phase of the GLP-1 boom was defined by shortages and brand-name manufacturers sparring with compounding pharmacies. The next phase will be marked by Medicare coverage expansions and new ...

Ms. Belluz is a contributing Opinion writer covering health, nutrition and chronic illness. See more of our coverage in your search results.Encuentra más de nuestra cobertura en los resultados de ...

Jessica Rendall is a reporter with experience covering a variety of health and wellness topics, including chronic disease, infectious disease, telemedicine, mental health and health technology. Emily ...

The weight-loss drug rivalry heats up as another GLP-1 pill gains FDA approval This week the U.S. Food and Drug Administration approved a second GLP-1 pill for weight loss. The drug, called Foundayo, ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. There have been many headlines in the last week about $50 weight-loss drugs for Medicare ...

After capturing the North American market with Wegovy (semaglutide) and Zepbound (tirzepatide), Novo Nordisk A/S and Eli Lilly and Co. are advancing blockbuster glucagon-like peptide-1 (GLP-1) ...

Injectable GLP-1s have shown slightly higher effectiveness for weight loss in clinical trials compared to oral versions. Both forms share similar gastrointestinal side effects, such as nausea and ...

Megan McDonald, 36, of Boxford, Massachusetts, has noticed her shopping habits have changed in the two years she's been on a GLP-1. Since McDonald began using the GLP-1, Zepbound, and she lost 175 ...

With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift toward oral GLP-1 drugs. While Novo leverages its first-mover advantage with ...